Epidemiology, risk factors and outcomes of bloodstream infection caused by ESKAPEEc pathogens among hospitalized children

Xiaoshan Peng 1,2, Wei Zhou 3,2, Yu Zhu 1,2* and Chaomin Wan 1,2*

Abstract

Background: Bloodstream infection (BSI) resulting from ESKAPEEc pathogens (Enterococcus faecium, Staphylococcus aureus, Klebsiella pneumoniae, Escherichia coli, Acinetobacter baumannii, Pseudomonas aeruginosa and Enterobacter spp) is relevant to high mortality and economic cost. Data concerning the impact of BSI due to ESKAPEEc in pediatric population was virtually scant. Our purpose was to summarize the epidemiology, risk factors and outcomes of ESKAPEEc BSI among hospitalized children.

Methods: Inpatients diagnosed with BSI with definite etiology between January 2016 and December 2018 were enrolled retrospectively at the West China Second University Hospital. Data were systematically reviewed on patients’ clinical characteristics and laboratory findings to ascertain independent predictors, clinical features and outcomes.

Results: Of the 228 patients with BSI, 174 (76.3%) were caused by ESKAPEEc (124 MDR-ESKAPEEc). Multivariate analysis demonstrated that premature and/or low birth weight (odds ratio [OR] = 2.981, \( P = 0.036 \)), previous surgery and/or trauma (OR = 5.71, \( P = 0.029 \)) and source of urinary tract infection (OR = 10.60, \( P = 0.004 \)) were independently associated with ESKAPEEc BSI. The independent risk factor for MRD-ESKAPEEc BSI was nosocomial infection (OR = 3.314, \( P = 0.037 \)). The overall mortality rate in patients with ESKAPEEc BSI was 14.4% (25/174), and no significant difference was ascertained in mortality between MRD-ESKAPEEc and non-MRD ESKAPEEc BSI groups (13.7% vs. 11.4%, \( P = 0.692 \)). In addition, previous surgery and/or trauma, thrombocytopenia, and mechanical ventilation were significant risk factors for mortality caused by ESKAPEEc BSI.

Conclusions: More than two-thirds of BSI among hospitalized children were caused by ESKAPEEc. Previous surgery and/or trauma, thrombocytopenia and mechanical ventilation increased the risk rate for mortality in ESKAPEEc BSI. The risk factors ascertained could assist physicians to early suspect ESKAPEEc BSI and MDR ESKAPEEc BSI.

Keywords: ESKAPEEc pathogens, Bloodstream infection, Children

© The Author(s). 2021 Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
Background

The notorious group of pathogens, Enterococcus faecium, Staphylococcus aureus, Klebsiella pneumoniae, Escherichia coli, Acinetobacter baumannii, Pseudomonas aeruginosa and Enterobacter spp., named “ESKAPEEc” owing to their high resistances to multiple antimicrobial agents, have recently aroused global concern [1, 2]. Currently, the incidence of bloodstream infection (BSI) caused by ESKAPEEc has increased rapidly [3], and ESKAPEEc BSI brought about worse outcomes [3], longer hospital stays, higher economic costs [4–6], and increased mortality [4–6]. In addition, effective antimicrobial agents against ESKAPEEc strains were limited due to the growth of resistance to multiple antibiotics in these bacterial species. Inappropriate and delayed empirical antimicrobial agents' treatment for patients with BSI was connected with high risk of mortality [7–10]. Therefore, a wide understanding of the main clinical characteristics of ESKAPEEc BSI among hospitalized children was crucial for physicians to early recognition and select proper empirical therapy.

To our knowledge, the existing studies have given attention to the epidemiology and antimicrobial resistance trends of ESKAPEEc in patients with BSI [11–13], and clinical data about ESKAPEEc BSI were mainly available in adult populations with cancer or solid organ transplantation [14–17]. So far, there was no data concerning the BSI caused by ESKAPEEc in pediatric populations. Thus, we sought to investigate the epidemiology, clinical characteristics among hospitalized children with ESKAPEEc BSI. Simultaneously, we also assessed risk factors, and clinical outcomes of them.

Methods

Study population

Hospitalized children who were diagnosed with BSI based on a positive blood culture between 2016 and 2018 at the West China Second University Hospital of Sichuan University and aged under 14 years old were enrolled retrospectively after obtaining ethics approval. The exclusion criteria were listed next (Fig. 1): (1) polymicrobial infections; (2) diagnosed with fungal BSI; (3) incomplete clinical data.

Data collection

This study obtained the following data from electronic medical records, including age, gender, previous hospitalization (within 1 month), history of surgery and/or trauma (within 3 months), records of previous antibiotic use (within 1 month), underlying diseases, nosocomial infection or not, symptoms, microbiology data (microorganisms and resistance to antimicrobial agents), likely source of infection, blood products transfusion, pediatric intensive care unit (PICU) admission, invasive operation (indwelling gastric tube, central venous catheter, urinary catheter, mechanical ventilation), empirical antibiotics therapy, length of hospital stay and patients’ clinical outcomes. Meanwhile, the additional laboratory results within the first 24 h of admission were collected: the blood routine, C-reactive protein, alanine aminotransferase (ALT) and aspartate aminotransferase (AST). This study was analyzed through three parts. First, all enrolled patients were classified into ESKAPEEc and non-ESKAPEEc groups to ascertain the risk factors of ESKAPEEc BSI. Second, risk factors of patients with BSI resulting from MRD ESKAPEEc were investigated by comparing the MRD ESKAPEEc and non-MRD ESKA
PENG et al. BMC Pediatrics (2021) 21:188

Page 3 of 10

PEEeC groups. Finally, the 174 patients with ESKAPEEc BSI according to patients’ final condition at discharge were divided into survivor and non-survivor groups to investigate the risk factors closely connected with mortality.

Definitions
BSI was defined as the causative bacteria isolated in the blood cultures and clinical manifestations in accordance with sepsis syndrome [18]. The diagnosis criteria were determined by the definitions of National Healthcare Safety Network and CDCP [19]. ESKAPEEc were previously defined elsewhere [1, 2, 4, 12]. The definition of MRD was based on the international expert proposal for interim standard [20]. Polymicrobial infection referred to ≥2 causative organisms isolated from a single blood culture [21]. Empirical antibiotic treatment was regarded as being “appropriate” if the isolated causative organisms were susceptible to ≥1 of the antimicrobial agents administered in vitro. Otherwise, the treatment was considered to be “inappropriate”. Overall mortality referred to death by any cause during hospitalization. Some children who had multiple organ failure, demanded inotropes support or mechanical ventilation were discharged from hospital voluntarily and gave up any further treatment. These children were considered non-survivor groups within this period.

Microbiological Methods
The blood cultures were fulfilled strictly in accordance with the standard operating procedures. The causative bacteria identification and antibiotic resistance testing were conducted using the VITEK 2 (BioMérieux, Marcy-l’Etoile, France) system. The interpretation criteria of antibiotic resistance tests was determined by the definitions of Clinical and Laboratory Standards Institute [22].

Statistical analysis
We reported the median (interquartile range [IQR]) for measurement dates and analyzed them using Mann-Whitney U test appropriately. We calculated constituent ratios for count dates and analyzed them utilizing the χ² test or Fisher’s exact test. Variables in the univariate analysis that exhibited statistical differences (P-value < 0.05) were placed into the binary logistic regression analysis to investigate factors potentially associated with ESKAPEEc BSI, MRD-ESKAPEEc BSI and mortality. All dates were implemented with the SPSS version 22.0. P-values < 0.05 were deemed significant.

Results
Two hundred fifty-two hospitalized pediatric patients were diagnosed with laboratory-confirmed BSI Between 2016 and 2018 at the West China Second Hospital, Sichuan University. Twenty-four patients were not included according to the exclusion criteria (Fig. 1); Ultimately, we identified 228 patients in this study. One hundred seventy-four of the 228 patients (76.3%) had ESKAPEEc BSI. Six of the 174 (3.4%) patients lacked resistance data; 124 (73.8%) were MDR ESKAPEEc and 44 (26.2%) were non-MDR ESKAPEEc.

Microbiology
As Table 1 showed, the two leading ESKAPEEc pathogens were Escherichia coli (26.8%,61/228), Klebsiella pneumoniae (20.2%,46/228), followed by Enterococcus faecium (12.7%, 29/228), Staphylococcus aureus (12.7%, 29/228), Acinetobacter baumannii (2.6%, 6/228), Pseudomonas aeruginosa (1.3%, 3/228) and Enterobacter spp. (0). Of the 124 MDR ESKAPEEc strains, Escherichia coli and Klebsiella pneumoniae accounted for nearly 65.3%. 42 (33.9%) were ESBL-producing bacteria, including Escherichia coli (28,22.6%) and Klebsiella pneumoniae (14,11.3%). 20 (16.1%) were carbapenem-nonsusceptibility bacteria, including Klebsiella pneumoniae (15,12.1%), Escherichia coli (3,2.4%) and Acinetobacter baumannii (2,1.6%). In addition, there were 1 vancomycin-resistant Enterococcus faecium and 8 methicillin-resistant Staphylococcus aureus.

Comparison of ESKAPEEc and non-ESKAPEEc BSI
The main characteristics of patients with ESKAPEEc and non-ESKAPEEc BSI were summarized in Table 2. Less than half of the patients were males (42.1%, 96/228) and the median age was 4.4 (range:0.7–35.7) months. The median age between the two groups (median month, 2.5 [0.5–12.3] vs 32.7[8.0–100.4], P < 0.001) showed statistically significant difference. Regarding underlying disease, a greater proportion of premature and/or low birth

Table 1 Bacteria isolated in hospitalized children with bloodstream infection

| Organism                   | N (%) | MDR ESKAPEEc, N(%) |
|----------------------------|-------|--------------------|
| Enterococcus faecium       | 29 (12.7) | 23 (18.5) |
| Staphylococcus aureus      | 29 (12.7) | 12 (9.7) |
| Klebsiella pneumoniae      | 46 (20.2) | 34 (27.4) |
| Pseudomonas aeruginosa     | 3 (1.3) | 3 (2.4) |
| Acinetobacter baumannii    | 6 (2.6) | 5 (4.0) |
| Enterobacter spp           | 0     | 0 |
| Escherichia coli           | 61 (26.8) | 47 (37.9) |
| Streptococcus pneumoniae   | 27 (11.8) |               |
| Group B Streptococcus      | 9 (3.9) |               |
| Enterococcus faecalis      | 5 (2.2) |               |
| Salmonella spp             | 13 (5.7) |               |
| Total                      | 228 (100) | 124 (100) |

Abbreviations: MDR multidrug resistance
### Table 2: Comparison of ESKAPEEc and non-ESKAPEEc bloodstream infections among hospitalized children

| Variable                                           | ESKAPEEc n = 174 | Non-ESKAPEEc n = 54 | Univariate analysis | Logistic Regression Analysis<sup>a</sup> |
|----------------------------------------------------|-------------------|---------------------|---------------------|------------------------------------------|
| Male, No. (%)                                      | 71 (40.8)         | 25 (46.3)           | 0.475               |                                          |
| Age (m), Median (IQR)                              | 2.5 (0.5–12.3)    | 32.7 (8–100.4)      | < 0.001             | 0.367                                    |
| Presence of any underlying disease, No. (%)        | 111 (63.8)        | 14 (25.9)           | < 0.001             | 1.004 (0.995–1.014)                      |
| Premature and/or low birth weight, No. (%)         | 55 (31.6)         | 5 (9.3)             | 0.001               | 0.036                                    |
| Tumor diseases, No. (%)                            | 29 (16.7)         | 0                   | < 0.001             | 0.026                                    |
| Aplastic anemia, No. (%)                           | 3 (1.7)           | 2 (3.7)             | 0.737               |                                          |
| Congenital heart disease, No. (%)                  | 11 (6.3)          | 1 (1.9)             | 0.349               |                                          |
| Lung disease, No. (%)                              | 12 (6.9)          | 1 (1.9)             | 0.289               |                                          |
| Digestive disease, No. (%)                         | 15 (8.6)          | 1 (1.9)             | 0.163               |                                          |
| Kidney disease, No. (%)                            | 4 (2.3)           | 1 (1.9)             | 1.000               |                                          |
| Other diseases, No. (%)                            | 11 (6.3)          | 3 (5.6)             | 1.000               |                                          |
| Nosocomial infection, No. (%)                      | 56 (32.2)         | 4 (7.4)             | < 0.001             | 0.579                                    |
| Previous surgery and/ or trauma (within 3 months), No. (%) | 24 (13.8)       | 2 (3.7)             | 0.042               | 0.029                                    |
| Previous hospitalization (within 1 month), No. (%) | 33 (19.0)         | 7 (13.0)            | 0.311               |                                          |
| Previous antibiotic use (within 1 month), No. (%)  | 45 (25.9)         | 27 (50.0)           | 0.001               |                                          |
| Penicillins, No. (%)                               | 8 (4.6)           | 7 (13.0)            | 0.064               |                                          |
| Cephalosporins, No. (%)                            | 21 (12.1)         | 18 (33.3)           | < 0.001             | 0.168                                    |
| β-lactam-β-lactamase inhibitor combination regimens, No. (%) | 18 (10.3)       | 3 (5.6)             | 0.427               |                                          |
| Carbapenems, No. (%)                               | 6 (3.4)           | 2 (3.7)             | 1.000               |                                          |
| Macrolides, No. (%)                                | 1 (0.6)           | 3 (5.6)             | 0.065               |                                          |
| Glycopeptides, No. (%)                             | 8 (4.6)           | 0                   | 0.238               |                                          |
| Others, No. (%)                                    | 1 (0.6)           | 3 (5.6)             | 0.065               |                                          |
| Likely source of infections                        |                   |                     |                     |                                          |
| Lung infection, No. (%)                            | 31 (17.8)         | 23 (42.6)           | < 0.001             | 0.098                                    |
| Abdominal infection, No. (%)                       | 27 (15.5)         | 5 (9.3)             | 0.247               |                                          |
| Urinary infection, No. (%)                         | 26 (14.9)         | 1 (1.9)             | 0.009               | 0.004                                    |
| Intracranial infection, No. (%)                    | 2 (1.1)           | 9 (16.7)            | < 0.001             | 0.037                                    |
| Skin or soft tissue infection, No. (%)             | 20 (11.5)         | 1 (1.9)             | 0.061               |                                          |
| Primary BSI, No. (%)                               | 75 (43.1)         | 16 (29.6)           | 0.077               |                                          |
| Laboratory findings                                |                   |                     |                     |                                          |
| White blood cell count (*10^9), Median (IQR)       | 9.4 (5.0–13.7)    | 11.1 (6.4–17.0)     | 0.106               |                                          |
| Neutrophil percentage, Median (IQR)                | 56.0 (33.9–71.8)  | 56.9 (37.4–76.5)    | 0.370               |                                          |
| Hemoglobin (g/L), Median (IQR)                     | 108.0 (93.0–144.5)| 106.0 (90.3–125.0)  | 0.272               |                                          |
| Platelet count (*10^9), Median (IQR)               | 209 (111–323)     | 341 (168–439)       | < 0.001             | 0.142                                    |
| C-reactive protein (mg/dL), Median (IQR)           | 15.0 (3.0–85.3)   | 26.5 (10.0–116.6)   | 0.017               | 0.704                                    |
| Elevated ALT, No. (%)                              | 56 (32.2)         | 20 (37.0)           | 0.509               |                                          |
| Elevated AST, No. (%)                              | 90 (51.7)         | 21 (38.9)           | 0.099               |                                          |
| Severity of BSI                                    |                   |                     |                     |                                          |
| MODS, No. (%)                                      | 15 (8.6)          | 6 (11.1)            | 0.777               |                                          |
| Septic shock, No. (%)                              | 13 (7.5)          | 2 (3.7)             | 0.508               |                                          |
| Mechanical ventilation, No. (%)                   | 44 (25.3)         | 13 (24.1)           | 0.857               |                                          |
weight (31.6% vs 9.3%, $P = 0.001$), tumor diseases (16.7% vs 0%, $P < 0.001$) was presented in patients with ESKAPEc BSI. Compared with non-ESKAPEc BSI, patients with BSI caused by ESKAPEc had increased percentages of previous surgery and/or trauma (13.8% vs 3.7%, $P = 0.042$), nosocomial infection (32.2% vs 7.4%, $P < 0.001$), more source of urinary tract infection (25.9% vs 50.0%, $P = 0.001$), lower rate of previous antibiotic use (25.9% vs 31.6%, $P < 0.001$), but lower rate of previous antibiotic use (25.9% vs 50.0%, $P = 0.001$), less source of lung infection (17.8% vs 50.0%, $P = 0.001$), intracranial infection (1.1% vs 16.7%, $P < 0.001$) and lower levels of platelet count (median, 209 [111–323] vs 341 [168–439], $P < 0.001$), C-reactive protein (median mg/dL, 15.0 [3.0–85.3] vs 26.5 [10.0–116.6], $p = 0.017$). After applying the multivariate analysis, premature and/or low birth weight (odds ratio [OR] = 2.981, $P = 0.036$), previous surgery and/or trauma (OR = 5.71, $P = 0.029$) and source of urinary tract infection (OR = 10.6, $P = 0.004$) were independent risk factors for ESKAPEc BSI. Source of intracranial infection was a protective factor for ESKAPEc BSI (OR = 0.198, $P = 0.037$).

In terms of empiric antimicrobial treatment and outcomes of all cases, we found that 50 of the 228 patients (21.9%) were treated inappropriately: 46 (27.4%, 46/168) were in ESKAPEc BSI patient group and 4 (7.4%, 4/54) were in non-ESKAPEc BSI group. Patients with ESKAPEc BSI had received inappropriate empiric antibiotics treatment significantly more often (27.4% vs 7.4%, $p = 0.003$) (Table 2). Although no significant differences in the MODS, septic shock, mechanical ventilation, PICU admission and mortality between ESKAPEc and non-ESKAPEc BSI groups were found (all $p > 0.05$). Patients with BSI due to ESKAPEc had longer hospital stay (median days, 20.5 [10.0–31.0] vs 14.0 [8.8–23.0], $p = 0.023$) compared with those with non-ESKAPEc BSI.

**Comparison of MDR ESKAPEc and non-MDR ESKAPEc BSI**

The 168 patients with resistance data were divided into MDR ESKAPEc and non-MDR ESKAPEc BSI groups. The differences of the main characteristics between the 2 groups were showed in Table 3. MDR ESKAPEc patients with BSI had more nosocomial infections (41.1% vs 11.4%, $P < 0.001$) and the presence of underlying disease (72.6% vs 43.2%, $P < 0.001$) was also higher, whereas the age and sex between the 2 groups were not statistically different. Compared with non-MDR ESKAPEc BSI, patients with MDR-ESKAPEc BSI were less likely to have a history of antibiotic use within 1 month (21.8% vs 43.2%, $P = 0.006$), source of skin or soft tissue infection (6.5% vs 27.3%, $P < 0.001$). Furthermore, the median level of platelet count was significantly lower in MDR-ESKAPEc group with BSI than that in non-MDR ESKAPEc group (median, 188 [100–302] vs 271 [173–413], $P = 0.004$). In multivariate analysis, the independent risk factor for MDR-ESKAPEc BSI was nosocomial infection (OR = 3.314, $P = 0.037$), while the skin or soft tissue infection (OR = 0.245, $P = 0.011$) was a protective predictor of MDR ESKAPEc BSI.

Regarding empiric antimicrobial treatment and outcomes for MDR ESKAPEc BSI, 42 of the 124 MDR-ESKAPEc patients with BSI (33.9%) were treated inappropriately in comparison with the 4 of the 44 non-MDR ESKAPEc patients with BSI (9.1%) ($P = 0.002$) (Table 3). Hospital stay in MDR-ESKAPEc BSI group was longer than that in non-MDR ESKAPEc BSI group (median days, 24.0 [13.0–36.0] vs 14.5 [9.0–27.3], $P = 0.006$) (Table 3). Whereas, no significant differences were ascertained in MODS, septic shock, mechanical ventilation, PICU admission, mortality between MDR and non-MDR ESKAPEc BSI groups (all $p > 0.05$).

**Predictors for mortality among hospitalized children with ESKAPEc BSI**

A total of 174 hospitalized children with ESKAPEc BSI were identified in our study. The overall mortality rate of these patients was 14.4% (25/174), and no significant difference was ascertained regarding mortality between MDR-ESKAPEc and non-MRD ESKAPEc BSI groups. The overall mortality rate of these patients was 14.4% (25/174), and no significant difference was ascertained regarding mortality between MDR-ESKAPEc and non-MRD ESKAPEc BSI groups.
Table 3: Comparison of MRD and non-MRD ESKAPEec bloodstream infections among hospitalized children

| Variable                              | MRD-ESKAPEec | Non-MRD ESKAPEec | Univariate analysis | Logistic Regression Analysis |
|---------------------------------------|--------------|------------------|--------------------|-----------------------------|
|                                       | n = 124      | n = 44           |                    |                             |
| Male, No. (%)                         | 50 (40.3)    | 18 (40.9)        | 0.946              |                             |
| Age (m), Median (IQR)                 | 2.5 (0.5–26.4) | 9.7 (1.0–72.0)   | 0.07               |                             |
| Presence of any underlying disease, No. (%) | 90 (72.6)     | 19 (43.2)        | < 0.001            | 0.469 (0.581–3.26)         |
| Premature and/or low birth weight, No. (%) | 44 (35.5)     | 10 (22.7)        | 0.120              |                             |
| Tumor diseases, No. (%)               | 24 (19.4)    | 5 (11.4)         | 0.228              |                             |
| Aplastic anemia, No. (%)              | 3 (2.4)      | 0                | 0.568              |                             |
| Congenital heart disease, No. (%)     | 10 (8.1)     | 1 (2.3)          | 0.327              |                             |
| Lung disease, No. (%)                 | 11 (8.9)     | 1 (2.3)          | 0.263              |                             |
| Digestive disease, No. (%)            | 14 (11.3)    | 1 (2.3)          | 0.135              |                             |
| Kidney disease, No. (%)               | 3 (2.4)      | 1 (2.3)          | 1.000              |                             |
| Other diseases, No. (%)               | 7 (5.6)      | 3 (6.8)          | 1.000              |                             |
| Nosocomial infection, No. (%)         | 51 (41.1)    | 5 (11.4)         | < 0.001            | 0.037 (3.314 (1.076–10.205) |
| Previous surgery and/ or trauma (within 3 months), No. (%) | 20 (16.1)     | 4 (9.1)          | 0.252              |                             |
| Previous hospitalization (within1 month), No. (%) | 27 (21.8)     | 6 (13.6)         | 0.243              |                             |
| Previous antibiotic use (within 1 month), No. (%) | 27 (21.8)     | 19 (43.2)        | 0.006              | 0.219 (0.6 (0.266–1.356)   |
| Likely source of infections           |              |                  |                    |                             |
| Lung infection, No. (%)               | 27 (21.8)    | 4 (9.1)          | 0.062              |                             |
| Abdominal infection, No. (%)          | 20 (16.1)    | 7 (15.9)         | 0.973              |                             |
| Urinary infection, No. (%)            | 17 (13.7)    | 9 (20.5)         | 0.288              |                             |
| Intracranial infection, No. (%)       | 2 (1.6)      | 0                | 1.000              |                             |
| Skin or soft tissue infection, No. (%) | 8 (6.5)       | 12 (27.3)        | < 0.001            | 0.011 (0.245 (0.083–0.721) |
| Primary BSI, No. (%)                  | 55 (44.4)    | 14 (31.8)        | 0.146              |                             |
| Laboratory findings                   |              |                  |                    |                             |
| White blood cell count (*10^9),Median (IQR) | 9.4 (4.9–13.9) | 9.8 (7.0–13.3)  | 0.358              |                             |
| Neutrophil percentage, Median (IQR)   | 54.0 (33.4–71.0) | 58.8 (41.0–76.9) | 0.082              |                             |
| Hemoglobin (gL), Median (IQR)         | 110.0 (91.8–150.0) | 104.5 (94.0–126.0) | 0.424              |                             |
| Platelet count (*10^9), Median (IQR)  | 188 (100–302) | 271 (173–413)    | 0.004              |                             |
| C-reactive protein (mg/dL), Median (IQR) | 9.5 (3.0–65.8) | 32.5 (2.3–150.7) | 0.203              |                             |
| Elevated ALT, No. (%)                 | 39 (31.5)    | 13 (29.5)        | 0.814              |                             |
| Elevated AST, No. (%)                 | 68 (54.8)    | 18 (40.9)        | 0.112              |                             |
| Severity of BSI                       |              |                  |                    |                             |
| MODS, No. (%)                         | 12 (9.7)     | 1 (2.3)          | 0.211              |                             |
| Septic shock, No. (%)                 | 10 (8.1)     | 0                | 0.065              |                             |
| Mechanical ventilation, No. (%)       | 32 (25.8)    | 10 (22.7)        | 0.685              |                             |
| PICU admission, No. (%)               | 18 (14.5)    | 11 (25.0)        | 0.114              |                             |
| Length of hospital stay (days), Median (IQR) | 24.0 (13.0–36.0) | 14.5 (9.0–27.3) | 0.006              |                             |
| 7-day mortality                       | 8 (6.5)      | 3 (6.8)          | 1.000              |                             |
| Overall mortality                     | 17 (13.7)    | 5 (11.4)         | 0.692              |                             |
| Inappropriate empirical treatment, No. (%) | 42 (33.9)    | 4 (9.1)          | 0.002              |                             |

MDR multidrug resistant. The interpretation for the other abbreviations were listed in Table 2 legend
Elevated ALT means ALT was > 40 U/L. Elevated AST means AST was > 45 U/L
* P value of Hosmer-Lemeshow goodness-of-fit test was 0.668

(13.7% vs. 11.4%, P = 0.692) (Table 3). In the univariate analysis (Table 4), previous surgery and/or trauma, previous antibiotic use, neutrophil percentage, hemoglobin, platelet count, MODS, blood products transfusion, mechanical ventilation, PICU admission were statistically differences between survivor and non-survivor groups
Table 4  Analysis of predictors for mortality in 174 hospitalized children with ESKAPEec BSI

| Variable                                      | non-survivors, n = 25 | survivors, n = 149 | Univariate analysis | Logistic Regression Analysis* |
|-----------------------------------------------|------------------------|--------------------|---------------------|------------------------------|
|                                               |                        |                    | P Value             | P Value                      | Odds Ratio (95% CI)         |
| Male, No. (%)                                 | 10 (40.0)              | 61 (40.9)          | 0.930               |                              |                             |
| Age (m), Median (IQR)                         | 3.6 (0.8–33.5)         | 3.0 (0.6–36.0)     | 0.909               |                              |                             |
| Presence of any underlying disease, No. (%)   | 20 (80.0)              | 91 (61.1)          | 0.068               |                              |                             |
| Premature and/or low birth weight, No. (%)    | 8 (32.0)               | 47 (31.5)          | 0.964               |                              |                             |
| Tumor diseases, No. (%)                       | 4 (16.0)               | 25 (16.8)          | 1.000               |                              |                             |
| Aplastic anemia, No. (%)                      | 1 (4.0)                | 2 (1.3)            | 0.909               |                              |                             |
| Congenital heart disease, No. (%)             | 1 (4.0)                | 10 (6.7)           | 0.943               |                              |                             |
| Lung disease, No. (%)                         | 1 (4.0)                | 11 (7.4)           | 0.848               |                              |                             |
| Digestive disease, No. (%)                   | 5 (20.0)               | 10 (6.7)           | 0.071               |                              |                             |
| Kidney diseases, No. (%)                     | 1 (4.0)                | 3 (2.0)            | 1.000               |                              |                             |
| Other disease, No. (%)                        | 4 (16.0)               | 7 (4.7)            | 0.088               |                              |                             |
| Nosocomial infection, No. (%)                 | 5 (20.0)               | 51 (34.2)          | 0.156               |                              |                             |
| Previous surgery and/ or trauma (within 3 months), No. (%) | 8 (32.0)               | 16 (10.7)          | 0.011               | 0.006                        | 7.006 (1.761–27.876)       |
| Previous hospitalization (within 1 month), No. (%) | 5 (20.0)               | 28 (18.8)          | 1.000               |                              |                             |
| Previous antibiotic use (within 1 month), No. (%) | 2 (8.0)                | 45 (30.2)          | 0.021               | 0.034                        | 0.132 (0.020–0.860)        |
| Likely source of infections                   |                        |                    |                     |                              |                             |
| Lung infection, No. (%)                       | 5 (20.0)               | 26 (17.4)          | 0.979               |                              |                             |
| Abdominal infection, No. (%)                 | 6 (24.0)               | 21 (14.1)          | 0.333               |                              |                             |
| Urinary infection, No. (%)                   | 1 (4.0)                | 25 (16.8)          | 0.175               |                              |                             |
| Intracranial infection, No. (%)              | 0                      | 2 (1.3)            | 1.000               |                              |                             |
| Skin or soft tissue infection, No. (%)       | 0                      | 20 (13.4)          | 0.082               |                              |                             |
| Primary BSI, No. (%)                         | 12 (48.0)              | 63 (42.3)          | 0.593               |                              |                             |
| Laboratory findings                          |                        |                    |                     |                              |                             |
| White blood cell count (*10^9), Median (IQR) | 6.9 (3.5–11.3)         | 9.7 (5.3–13.9)     | 0.095               |                              |                             |
| Neutrophil percentage, Median (IQR)          | 41.0 (9.5–63.1)        | 58.0 (34.8–72.7)   | 0.019               | 0.072                        | 0.979 (0.957–1.002)        |
| Hemoglobin (g/L), Median (IQR)               | 97.0 (72.5–138.0)      | 110 (95–147.5)     | 0.026               | 0.218                        | 0.990 (0.973–1.006)        |
| Platelet count (*10^9), Median (IQR)         | 134 (41–227)           | 216 (117.5–352.0)  | 0.002               | 0.037                        | 0.996 (0.991–1.000)        |
| C-reactive protein (mg/dL), Median (IQR)     | 29 (6–132)             | 13 (3–80.5)        | 0.068               |                              |                             |
| Elevated ALT, No. (%)                        | 12 (48.0)              | 44 (29.5)          | 0.067               |                              |                             |
| Elevated AST, No. (%)                        | 15 (60.0)              | 75 (50.3)          | 0.371               |                              |                             |
| MODS, No. (%)                                | 7 (28.0)               | 8 (5.4)            | 0.001               | 0.752                        | 1.288 (0.268–6.197)        |
| Septic shock, No. (%)                        | 4 (16.0)               | 9 (6.0)            | 0.180               |                              |                             |
| Blood products transfusion, No. (%)          | 23 (92.0)              | 103 (69.1)         | 0.018               | 0.581                        | 0.597 (0.096–3.720)        |
| Indwelling catheter, No. (%)                 | 19 (76.0)              | 96 (64.4)          | 0.258               |                              |                             |
| Indwelling gastric tube, N(%)                | 14 (56.0)              | 61 (40.9)          | 0.159               |                              |                             |
| Central venous catheter, N(%)                | 10 (40.0)              | 66 (44.3)          | 0.689               |                              |                             |
| Urinary catheter, N(%)                       | 2 (8.0)                | 5 (3.4)            | 0.587               |                              |                             |
| Mechanical ventilation, N(%)                 | 13 (52.0)              | 31 (20.8)          | 0.001               | 0.004                        | 7.997 (1.906–33.546)       |
| PICU admission, No. (%)                      | 9 (36.0)               | 22 (14.8)          | 0.022               | 0.137                        | 3.065 (0.701–13.408)       |
| Inappropriate empirical treatment, No. (%)   | 9 (40.9)*              | 37 (25.3)*         | 0.127               |                              |                             |

* The interpretation for the abbreviations were listed in Table 2 legend

Elevated ALT means ALT was > 40 U/L. Elevated AST means AST was > 45 U/L.
* P value of Hosmer-Lemeshow goodness-of-fit test was 0.098
*Percentage derived from the results of non-survivors group (n=2) and survivors group (n=146) with resistance data
(all $p < 0.05$). A multivariate analysis demonstrated that previous surgery and/or trauma (OR = 7.006, $P = 0.006$), mechanical ventilation (OR = 7.997, $P = 0.004$) appeared to be effective predictors for death. Previous antibiotic use (OR = 0.132, $P = 0.034$), normal platelet count (OR = 0.996, $P = 0.037$) were protective factors for death caused by ESKAPEEc BSI.

**Discussion**

Data concerning the burden of ESKAPEEc BSI in hospitalized children was indeed non-existent. Existing information was mainly in adult population with definite underlying diseases. There were several findings identified in this study: (1) 76.3% ($n$ = 174) of BSIs among hospitalized children were caused by ESKAPEEc (124 MDR-ESKAPEEc). (2) Several risk factors for BSI due to ESKAPEEc and associated with BSI caused by MDR ESKAPEEc were identified. (3) The overall mortality rate in patients with ESKAPEEc BSI was 14.4% (25/174), and no significant difference was ascertained in mortality rate between MRD-ESKAPEEc and non-MRD ESKAPEEc BSI groups (13.7% vs. 11.4%, $P = 0.692$). (4) Several predictors for mortality among hospitalized children with ESKAPEEc BSI were also summarized.

In the current study, 76.3% of BSIs were caused by ESKAPEEc, which was similar to the previous reports in Southwest China (58.7%) [12] and Rome (61.7%) [13], but higher than that in the US (27.2%) [11]. This discrepancy may be associated with geographical regions and study population. Previous studies frequently reported MDR bacteria were *Escherichia coli* and *Klebsiella pneumoniae*, most of which trended to be ESBL-producing organisms [23–25]. Furthermore, an upward trend in the proportion of ESBL-producing Enterobacteriaceae ESKAPEEc BSI was found [12]. Similarly, a high rate of MRD-ESKAPEEc BSI resulting from an ESBL-producing strain among children was also observed in this study. One common reason in many developing countries which may result in the high incidence of antibiotic resistant BSI was the overuse and misuse of antibiotics. Meanwhile, our study revealed that the most common carbapenem non-susceptibility strains were *Klebsiella pneumoniae* (6.8%, 15/222), which was consistent with data reported by CHINET (5.5%) [26], but differed from the result from southwest China (12.8%) [12]. Studies have shown that carbapenem-resistant *Klebsiella pneumoniae* (CRKP) was relevant to high mortality [27, 28]. Yet the treatment regimens for CRKP BSI were limited in clinic. CRKP infections have posed an extreme antibiotic-resistant threat [28]. Thus, additional studies should concentrate on the molecular and epidemiological mechanism of CRKP.

To our knowledge, there was no study using multivariate analyses to investigate risk factors for ESKAPEEc BSI. In the present study, we found that premature and/or low birth weight, previous surgery and/or trauma and source of urinary tract infection were independent risk factors for ESKAPEEc BSI. Moreover, there was only two studies among adult population focusing on the risk factors for drug-resistant ESKAPEEc BSI in multivariate analyses [14, 15]. Gudiol C, et al. in 2014 have found that drug-resistant ESKAPEEc bacteremia were significantly associated with underlying diseases, previous antibiotic use, and source of urinary tract infection [14]. Marta B, et al. in 2013 have revealed that solid-organ transplant patients who had previous antibiotic use and septic shock were more likely to develop drug-resistant ESKAPEEc bacteremia [15]. Based on the existing information, it was likely that underlying diseases, previous invasive operation, previous antibiotic use and source of infection were the key factors for MRD-ESKAPEEc BSI. We further investigated the independent risk factor for MRD ESKAPEEc patients with BSI was nosocomial infection (OR = 3.314, $P = 0.037$). This result was not in line with those risk factors ascertained in the previous studies [14, 15]. The discrepancies may be owing to the diverse study population, diverse definition of MRD [14–17], diverse inclusion criteria [14–17]. Various studies have showed that ESKAPEEc pathogens, especially MRD-ESKAPEEc, have emerged as the predominant opportunistic organisms responsible for nosocomial infections [29–31], resulting in severe infection. Accompanying by nosocomial infection, there was urgently need for empiric treatment to cover MRD-ESKAPEEc pathogens among children with BSI. The association between bacterial resistance development and previous antibiotic use remained inconsistent. Some studies revealed that previous antibiotic exposure (especially carbapenem) was an independent risk factor for MRD pathogens infection [14, 15, 28, 32]. Conversely, other study has demonstrated no association was identified between MRD bacterial infections and previous antibiotic use [33], in accordance with our data. Thus, further association between bacterial resistance development and antibiotic use previous to infection need to be monitored closely.

To explore the possible influence of MRD pathogens for the outcome of patients with ESKAPEEc BSI, patients’ characteristics were systematically evaluated. The overall mortality rate among children with ESKAPEEc BSI was 14.4% (25/174), and no significant difference was ascertained in mortality between MRD-ESKAPEEc and non-MRD ESKAPEEc BSI patients (13.7% vs. 11.4%, $P = 0.692$), which was in accordance with previous studies [16, 17]. This finding reflected the fact that MRD-ESKAPEEc was not a risk factor associated with worse outcome, and although resistant strains were not easily to cure, might be less virulent. Moreover, previous
studies have reported various predictors of poor outcome in patients with ESKAPEeC BSI, including female sex [16], lymphocyte counts < 300/mm³ [16], corticosteroid therapy [14] and β-lactam monotherapy [14], septic shock [16, 17], ICU admission [14]. In our study, we found that mechanical ventilation (OR = 7.997, \(P = 0.004\)) was the strongest risk factor associated with mortality. Further, previous surgery and/or trauma and thrombocytopenia increased the risk rates for mortality among children with ESKAPEeC BSI. Thrombocytopenia was a well-known indicator of serious infections development [34, 35], which can be considered an early screening tool for poor outcome in children with ESKAPEeC BSI. Low platelet count resulting from bacterial infection was recorded closely and tended to indicate impaired production caused by bone marrow suppression and/or increased destruction owing to endothelial cell injury and platelet aggregation [36–38].

Though it is the first time to summarize the main characteristics of ESKAPEeC BSI among hospitalized children, several limitations exist. First, our study is a single-center study representing most of the pediatric population in the Southwest China, some findings may not be generalizable to other settings. Second, selection and recall bias occurred inevitably due to the retrospective analysis and these variations may partly affect the findings of the study.

**Conclusions**

The present study revealed that more than two-thirds of BSI among hospitalized children were caused by ESKAPEeC. It also demonstrated that previous surgery and/or trauma, thrombocytopenia and mechanical ventilation increased the risk rate for mortality in ESKAPEeC BSI. The risk factors ascertained could assist physicians to early suspect ESKAPEeC BSI and MDR ESKAPEeC BSI.

**Abbreviations**

ALT: Alanine aminotransferase; AST: Aspartate aminotransferase; BSI: Bloodstream infection; CI: Confidence interval; MODS: Multiple organ dysfunction syndrome; MDR: Multidrug resistant; IQR: Interquartile range; OR: Odds ratio; PICU: Pediatric intensive care unit

**Acknowledgements**

Not applicable.

**Authors’ contributions**

XP, YZ and CW designed this research. WZ and XP collected the data. XP interpreted the data and wrote the manuscript. YZ and CW revised the manuscript. All authors read and approved the final manuscript.

**Funding**

This study was supported by a grant from the Pediatric Clinical Research Center Foundation of Sichuan Province, China (No.2017-46-4). The funders had no role in the study design, collection, analysis, and interpretation of data or in writing the manuscript.

**Availability of data and materials**

The datasets used during the current study are available from the corresponding author on reasonable request.

**Declarations**

**Ethics approval and consent to participate**

Ethical approval for this study was approved by the medical committee of West China Second Hospital, Sichuan University. Owing to the retrospective design of this research, informed consent was waived. No administrative permissions were acquired to access the data used in this study.

**Consent for publication**

Not applicable.

**Competing interests**

The authors declare that they have no competing interests.

**Author details**

1. Department of Pediatrics, West China Second Hospital, Sichuan University, No 20, 3rd section of Renmin South Road, 610041 Chengdu, China. 2. Key Laboratory of Birth Defects and Related Diseases of Women and Children (Sichuan University), Ministry of Education, Chengdu, China. 3. Department of Clinical Microbiology Laboratory, West China Second Hospital, Sichuan University, Chengdu, China.

**Received: 29 July 2020 Accepted: 12 April 2021**

**References**

1. Boucher HW, Talbot GH, Bradley JS, Edwards JE, Gilbert D, Rice LB, et al. Bad bugs, no drugs: no ESKAPE! An. Update from the Infectious Diseases Society of America. Clin Infect Dis. 2009;48:1–12. https://doi.org/10.1086/595011.

2. Tacconelli E, Carrara E, Savoldi A, Harbarth S, Mendelson M, Monnet DL, et al. Discovery, research, and development. Of new antibiotics: the WHO priority list of antibiotic-resistant bacteria and tuberculosis. Lancet Infect Dis. 2018;18(9):318–27. https://doi.org/10.1016/S1473-3099(17)30753-3.

3. Pogue JM, Kaye KS, Cohen DA, Marchaim D. Appropriate antimicrobial therapy in the era of multidrug-resistant human pathogens. Clin Microbiol Infect. 2015;21(4):302–12.

4. Marturano JE, Lowry TJ. ESKAPE Pathogens in Bloodstream Infections Are Associated With Higher Cost and Mortality but Can Be Predicted Using Diagnoses Upon Admission. Open Forum Infect Dis. 2019;6(12):ofz503.

5. Zhen X, Lundborg CS, Sun X, Hu X, Dong H. Economic burden of antibiotic resistance in ESKAPE organisms: a systematic review. Antimicrob Resist Infect Control. 2019;8(1):137. https://doi.org/10.1186/s13756-019-0590-7.

6. Fournou RC, Fournou LL, Essack SY. Clinical and economic impact of antibiotic resistance in developing countries: a systematic review and meta-analysis. PLoS One. 2017;12:e0189621. https://doi.org/10.1371/journal.pone.0189621.

7. Martínez-Nadal G, Puerta-Alcalde P, Gudiel C, Cardoza C, Albasanz-Puig A, Marco F, et al. Inappropriate empirical antibiotic treatment in high-risk Neutropenic patients with bacteremia in the era of multidrug resistance. Clin Infect Dis. 2020;70(6):1068–74. https://doi.org/10.1093/cid/ciz319.

8. Tacconelli E, Cataldo MA, Mutters NT, Carrara E, Bartoloni A, Raglio A, et al. Role of place of acquisition and inappropriate empirical antibiotic therapy on the outcome of extended-spectrum β-lactamase-producing Enterobacteriaceae infections. Int J Antimicrob Agents. 2019;54(1):49–54. https://doi.org/10.1016/j.ijantimicag.2019.04.007.

9. Retamar P, Portillo MM, López-Prieto MD, Rodríguez-López F, de Cueto M, García MV, et al. Impact of inadequate empirical therapy on the mortality of patients with bloodstream infections: a propensity score-based analysis. Antimicrob Agents Chemother. 2012;56(1):472–8. https://doi.org/10.1128/AAC.00462-11.

10. Seymour CW, Gesten F, Prescott HC, Friedrich ME, Iwashyna TJ, Phillips GS, et al. Time to treatment and mortality during mandated emergency Care for Sepsis. N Engl J Med. 2017;376(23):2235–44. https://doi.org/10.1056/NEJMoa1703058.

11. Larus R, Gong W, Vendetti N, Sullivan KV, Localio R, Zaoutis TE, et al. Bloodstream infections in hospitalized children: epidemiology and antimicrobial susceptibilities. Pediatr Infect Dis J. 2016;35(5):S07–10. https://doi.org/10.1097/INF.0000000000001057.

12. Yang S, Xu H, Sun J, Sun S. Shifting trends and age distribution of ESKAPEeC resistance in bloodstream infection, Southwest China, 2012-2017.
Antimicrob Resist Infect Control. 2019;8(1):61. https://doi.org/10.1186/s13756-019-0499-1.

13. De Angelis G, Fiori B, Menchini G, Dinizua T, Liotti FM, Morandotti GA, et al. Incidence and antimicrobial resistance trends in bloodstream infections caused by ESKAPE and Escherichia coli at a large teaching hospital in Rome, a 9-year analysis (2007–2015). Eur J Clin Microbiol Infect Dis. 2018;37(9):1627–36. https://doi.org/10.1007/s10096-018-3292-9.

14. Bodro M, Gudiol C, Garcia-Vidal C, Tubau F, Contra A, Boix L, et al. Epidemiology, antibiotic therapy and outcomes of bacteremia caused by drug-resistant ESKAPE pathogens in cancer patients. Support Care Cancer. 2014;22(3):603–10. https://10.1007/s00520-013-2012-3.

15. Bodro M, Sabé N, Tubau F, Liścio L, Ballellas C, Roca J, et al. Risk factors and outcomes of bacteremia caused by drug-resistant ESKAPE pathogens in solid-organ transplant recipients. Transplantation. 2013;96:843–9. https://10.1097/TP.0b013e3182a49fd.

16. Song SH, Li XX, Wan QQ, Ye QF. Risk factors for mortality in liver transplant recipients with ESKAPE infection. Transplant Proc. 2014;46(10):3560–3. https://10.1016/j.transproceed.2014.08.049.

17. Ye QF, Zhao J, Wan QQ, Qiao BB, Zhou JD. Frequency and clinical outcomes of ESKAPE bacteria in solid organ transplantation and the risk factors for mortality. Transpl Infect Dis. 2014;16(5):767–74. https://10.1111/tid.12278.

18. Dellinger RP, Levy MM, Rhodes A, Annane D, Gerlach H, Opal SM, et al. Surviving Sepsis campaign: international guidelines for management of severe sepsis and septic shock. 2012. Intensive Care Med. 2013;39(2):165–283. https://10.1007/s00134-012-2799-8.

19. Centers for Disease Control and Prevention. CDC/ NHSN Surveillance Guidelines for Specific Types of Infections. Available at: https://www.cdc.gov/hhsn/PDFs/cpscManual/17pscNosInfDef_current.pdf. Accessed 15 March 2020.

20. Magorakos AP, Sriravasan A, Careby R, Carmeli Y, Falagas ME, Giske CG, et al. Multidrug-resistant, extensively drug-resistant and pandrug-resistant bacteria: an international expert proposal for interim standard definitions for acquired resistance. Clin Microbiol Infect. 2012;18(3):268–81. https://10.1111/j.1469-0691.2011.03570.x.

21. Zheng C, Zhang S, Chen Q, Zhong L, Huang T, Zhang X, et al. Clinical characteristics and risk factors of polymicrobial Staphylococcus aureus bloodstream infections. Antimicrob Resist Infect Control. 2020;9(1):76. https://10.1186/s13756-020-00741-6.

22. Clinical and Laboratory Standard Institute. Performance standards for antimicrobial susceptibility testing, twenty-sixth informational supplement, M100-S26. Wayne: Clin Lab Stand Institute; 2016.

23. Santajit S, Indrawatana N. Mechanisms of antimicrobial resistance in ESKAPE pathogens. Biomed Res Int. 2016;2475067.

24. Seni J, Mvakomya AA, Mashuda F, Marando R, Ahmed M, Delhimney R, et al. Deciphering risk factors for blood stream infections, bacteria species and antimicrobial resistance profiles among children under five years of age in North-Western Tanzania: a multicentre study in a cascade of referral health care system. BMC Pediatr. 2019;19(1):32. https://10.1186/s12887-019-1411-0.

25. Xiao T, Yang K, Zhou Y, Zhang S, Ji J, Ying C, et al. Risk factors and outcomes in non-transplant patients with extended-spectrum beta-lactamase-producing Escherichia coli bacteremia: a retrospective study from 2013 to 2016. Antimicrob Resist Infect Control. 2019;8(1):144. https://10.1186/s13756-019-0579-y.

26. Xu A, Zheng B, Xu Y, Huang GZ, Zhong NS, Zuo C. National epidemiology of carbapenem-resistant and extensively drug-resistant gram-negative bacteria isolated from blood samples in China in 2013. Clin Microbiol Infect. 2016;22(S1):S120–8. https://10.1016/j.cmi.2015.09.015.

27. Li Y, Li J, Hu T, Hu J, Song N, Zhang Y, et al. Five-year change of prevalence and risk factors for infection and mortality of carbapenem-resistant Klebsiella pneumoniae bloodstream infection in a tertiary hospital in North China. Antimicrob Resist Infect Control. 2020;9(1):79. https://10.1186/s13756-020-00728-3.

28. Xiao T, Zhu Y, Zhang S, Wang Y, Shen P, Zhuo C, et al. A retrospective analysis of risk factors and outcomes of Carbapenem-resistant Klebsiella pneumoniae bacteremia in nontransplant patients. J Infect Dis. 2020;221(Suppl 2):1574–83. https://10.1093/infdis/jiaa559.

29. Dramowski A, Madide A, Bekker A. Neonatal nosocomial bloodstream infections at a referral hospital in a middle-income country: burden, pathogens, antimicrobial resistance and mortality. Paediatr Int Child Health. 2015;35(3):265–72. https://10.1179/2046905515Y.0000000029.

30. Tian L, Sun Z, Zhang Z. Antimicrobial resistance of pathogens causing nosocomial bloodstream infection in Hubei Province, China, from 2014 to 2016: a multicenter retrospective study. BMC Public Health. 2018;18(1):1121. https://10.1186/s12889-018-6013-5.

31. Choi YJ, Kwak YG, Yoo H, Lee SO, Kim HB, Han SH, et al. Trends in the distribution and antimicrobial susceptibility of causative pathogens of device-associated infection in Korean intensive care units from 2006 to 2013: results from the Korean nosocomial infections surveillance system (KONIS). J Hosp Infect. 2016;92(4):363–71. https://10.1016/j.jhin.2016.06.001.

32. Tsai MH, Chu SM, Hsu JF, Lien R, Huang HR, Chiang MC, et al. Risk factors and outcomes for multidrug-resistant gram-negative bacteria in the NICU. Pediatrics. 2014;133(2):e322–9. https://10.1542/peds.2013-1248.

33. Aizawa Y, Shoji T, Ito K, Kasai M, Sakurai H, Toyofuku E, et al. Multidrug-resistant gram-negative bacterial bloodstream infections in Children’s hospitals in Japan, 2010-2017. Pediatr Infect Dis J. 2019;38(7):653–9. https://10.1097/INF.0000000000002273.

34. Furuchi M, Miyairi I. Risk factors for persistent bacteremia in infants with catheter-related bloodstream infection due to coagulase-negative Staphylococcus in the neonatal intensive care unit. J Infect Chemother. 2016;22(2):785–9. https://10.1016/j.jiac.2016.08.011.

35. Fica A, Bunster N, Allagia F, Olivares F, Porte L, Braun S, et al. Bacteremic pneumococcal pneumonia: serotype distribution, antimicrobial susceptibility, severity scores, risk factors, and mortality in a single center in Chile. Braz J Infect Dis. 2014;18(2):115–23. https://10.1016/j.bjid.2013.06.001.

36. Del Vecchio A. Evaluation and management of thrombocytopenic neonates in the intensive care unit. Early Hum Dev. 2014;90(Suppl 2):S51–6. https://10.1016/j.earlhumdev.2014.08.013.

37. De Stoppelaar SF, Van ‘t Veer C, Van der Poll T. The role of platelets in sepsis. Intensive Care Med. 2016;42(4):583–9. https://10.1007/s00134-016-4486-9.

38. Thrombolectomy SF, Van’t Veer C, Van der Poll T. The role of platelets in sepsis. Thromb Haemost. 2014;112(4):666–77. https://10.1160/TH14-02-0126.

39. Furuichi M, Miyairi I. Risk factors for persistent bacteremia in infants with catheter-related bloodstream infection due to coagulase-negative Staphylococcus in the neonatal intensive care unit. J Infect Chemother. 2016;22(2):785–9. https://10.1016/j.jiac.2016.08.011.

40. De Stoppelaar SF, Van ‘t Veer C, Van der Poll T. The role of platelets in sepsis. Thromb Haemost. 2014;112(4):666–77. https://10.1160/TH14-02-0126.

41. Piggozi L, Aron JP, Ball J, Cecconi M. Understanding platelet dysfunction in sepsis. Intensive Care Med. 2016;42(4):583–6. https://10.1007/s00334-015-4012-x.

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Ready to submit your research? Choose BMC and benefit from:
• fast, convenient online submission
• thorough peer review by experienced researchers in your field
• rapid publication on acceptance
• support for research data, including large and complex data types
• gold Open Access which fosters wider collaboration and increased citations
• maximum visibility for your research: over 100M website views per year

At BMC, research is always in progress.

Learn more biomedcentral.com/submissions